Oncode Institute
Emil Pot is the Co-Founder and CEO of Allero Therapeutics, a company that develops immunotherapies for allergic and autoimmune disease patients. Emil also holds a position in business development at Oncode Institute, an independent research institute focused on cancer research. Prior to this, Emil worked as a European Patent Attorney and in business development at NLO, a firm specializing in intellectual property. Emil was also a Co-Founder and General Counsel at ActoGeniX N.V. before its successful acquisition. With a background in law and patents, Emil has extensive experience in business development, patent law, and technology transfer.
This person is not in any offices
Oncode Institute
Oncode Institute is an independent institute dedicated to understanding cancer and translating research into practice. Oncode, starting from a deeper understanding of the basics of cancer, works to come up with better treatments and improved diagnostics. Our goal: helping more patients survive, improving the quality of life for those afflicted, and ultimately curing cancer. The complexity of cancer calls for strategic action and collaboration. Instead of new buildings, we are constructing a network, in which experienced, leading scientists and gifted young researchers at partner institutions strive together toward a greater, common goal, supported by KWF Kankerbestrijding and the Dutch Government. Because only by working together we can outsmart cancer. Official launch on February 5th, 2018 If you have any questions or suggestions, please feel free to contact us at anytime. info@oncode.nl